Quoin Pharmaceuticals Ltd. (QNRX): Total Liabilities
$7.27M
As of 2025-12-31
$8.04M
As of 2026-06-30
+1.0%
3-year compound annual growth
-1.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.27M | +11.8% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $6.50M | 0.0% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $6.51M | -7.7% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $7.05M | -18.9% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $8.70M | +9.0% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $7.99M | n/a | 2022-04-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $7.27M | +11.8% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $4.67M | +424.1% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $7.06M | +21.1% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $45.68M | +6.5% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $7.76M | +13.9% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $4.23M | -8.4% |
| Propanc Biopharma, Inc. (PPCB) | 2025-06-30 | $5.73M | +48.7% |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $145.73M | +20.9% |
Compare QNRX, NXTS, IXHL, EVFM side by side · Screen every company in Pharmaceutical Preparations ↗